Beam Therapeutics Inc (BEAM)vsRegeneron Pharmaceuticals Inc (REGN)
BEAM
Beam Therapeutics Inc
$29.40
-10.48%
HEALTHCARE · Cap: $2.99B
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.46%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 8997% more annual revenue ($14.92B vs $164.01M). REGN leads profitability with a 29.6% profit margin vs -40.2%. REGN earns a higher WallStSmart Score of 64/100 (C+).
BEAM
Avoid35
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BEAM.
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 324.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of -5.8% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : BEAM
The strongest argument for BEAM centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 324.9% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : BEAM
The primary concerns for BEAM are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
BEAM profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
BEAM carries more volatility with a beta of 2.20 — expect wider price swings.
BEAM is growing revenue faster at 324.9% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 35/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Beam Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?